BACKGROUND INFORMATION ON THE PROCEDURE 
1. 
Submission of the dossier 
The  applicant  Sanofi-Synthelabo  submitted  on  20  December  1999  an  application  for  Marketing 
Authorisation  to  the  European  Agency  for  the  Evaluation  of  Medicinal  Products  (EMEA)  for 
Fasturtec,  in  accordance  with  the  centralised  procedure  falling  within  the  scope  of  Part  A  of  the 
Annex to Council Regulation No (EEC) 2309/93 of 22 July 1993. 
The Rapporteur and Co-Rapporteur appointed by the CPMP were: 
Rapporteur:  Dr. H. Van Bronswijk 
Co-Rapporteur: 
Prof. Dr. J.H. Trouvin 
Licensing status: 
The product was not licensed in any country at the time of submission of the application. 
2. 
• 
• 
• 
• 
• 
• 
• 
Steps taken for the assessment of the product 
The procedure started on 21 January 2000. 
The  Rapporteur's  first  Assessment  Report  was  circulated  to  all  CPMP  members  on 
31 March 2000.  The  Co-Rapporteur's  first  Assessment  Report  was  circulated  to  all  CPMP 
members on 3 April 2000 . 
During  the  meeting  on  23-25  May 2000  the  CPMP  agreed  on  the  consolidated  List  of 
Questions to be sent to the applicant. The final consolidated List of Questions was sent to the 
applicant on 26 May 2000. 
The  company  submitted  the  responses  to  the  CPMP  consolidated  List  of  Questions  on 
7 September 2000. 
The Rapporteur circulated the Joint Rapporteur/Co-rapporteur response Assessment Report on 
the company’s responses to the List of Questions to all CPMP members on 25 October 2000.  
The company, Sanofi-Synthelabo, provided on 15 November 2000, a letter of undertaking on 
the follow-up measures to be fulfilled as requested by the CPMP.  
During  the  meeting  on  14-16 November  2000  the  CPMP,  in  the  light  of  the  overall  data 
submitted  and  the  scientific  discussion  within  the  Committee,  issued  a  positive  opinion  for 
granting a Marketing Authorisation to Fasturtec on 16 November 2000. 
       1/1 
                   EMEA 2005 
 
 
 
 
 
 
 
 
 
 
 
 
